ArticleVirology journal2011
Alpha-1 antitrypsin is a potential biomarker for hepatitis B.
Article in Virology journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes.Breast cancer (Tokyo, Japan) · 2023Article
- Bioinformatics analysis of prognostic value and immune cell infiltration ofAnnals of translational medicine · 2022Article
- A pilot study on some critical immune elements in HBV infection: evidence of Alpha-1 Antitrypsin as an immunological biomarker.Gastroenterology and hepatology from bed to bench · 2022Article
- Article
- Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients.Glycoconjugate journal · 2016Article
- Hepatic steatosis depresses alpha-1-antitrypsin levels in human and rat acute pancreatitis.Scientific reports · 2015Article
- iTRAQ-based proteomic analysis of hepatic tissues from patients with hepatitis B virus-induced acute-on-chronic liver failure.Experimental and therapeutic medicine · 2015Article
- SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.Oncotarget · 2015Article
- Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B.Clinical and molecular hepatology · 2014Article
- Differential expression of serum/plasma proteins in various infectious diseases: specific or nonspecific signatures.Proteomics. Clinical applications · 2014Review
- Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B.Carcinogenesis · 2014Article
- Serum proteome changes in dengue virus-infected patients from a dengue-endemic area of India: towards new molecular targets?Omics : a journal of integrative biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunction exertion of specific proteins are key factors in disease progression, thus the systematical identification of those specific proteins is a prerequisite to understand various diseases. Though many proteins have been verified to impact on hepatitis, no systematical protein screening has been documented to hepatitis B virus (HBV) induced hepatitis, hindering the comprehensive understanding to this severe disease.
aimTo identify the major proteins in the progression of HBV infection from mild stage to severe stage.
methodsWe performed an integrated strategy by combining two-dimensional electrophoresis (2-DE), peptide mass fingerprinting (PMF) analysis, and tissue microarray techniques to screen the functional proteins and detect the localization of those proteins.
resultsInterestingly, MS/MS identification revealed the expression level of alpha-1 antitrypsin (AAT) was significantly elevated in serum samples from patients with severe chronic hepatitis. Immunoblotting with a specific AAT antibody confirmed that AAT is highly expressed in serum samples from patients with hepatic carcinoma and severe chronic hepatitis. Furthermore, we observed that AAT is with highest expression in normal tissue and cells, but lowest in hepatic carcinoma and severe chronic hepatitis tissues and cells, suggesting the specific secretion of AAT from tissues and cells to serum.
conclusionThese results suggest the possibility of AAT as a potential biomarker for hepatitis B in diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.